High titer of serum antiphospholipid antibody levels in adult Henoch-Schönlein purpura and cutaneous leukocytoclastic angiitis

Arthritis Care and Research

Volumn 59, Issue 4, 2008, Pages 561-567

  Kawakami, Tamihiro ^a   Yamazaki, Masahide ^b   Mizoguchi, Masako ^a   Soma, Yoshinao ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BETA2 GLYCOPROTEIN 1 ANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; PHOSPHATIDYLSERINE PROTHROMBIN ANTIBODY; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANAPHYLACTOID PURPURA; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LEG DISEASE; LEUKOCYTOCLASTIC VASCULITIS; MALE; MICROSCOPIC POLYANGIITIS; PREVALENCE; PROTEINURIA; URINALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTIPHOSPHOLIPID; FEMALE; HUMANS; MALE; MIDDLE AGED; PURPURA, SCHOENLEIN-HENOCH; VASCULITIS, HYPERSENSITIVITY;

EID: 42449083336     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.23528     Document Type: Article

References (27)

1. Knight JF. The rheumatic poison: a survey of some published investigations of the immunopathogenesis of Henoch-Schönlein purpura. Pediatr Nephrol 1990;4:533-41.
2. Jennette JC, Falk RJ, Andrassy K, Bacon PA, Churg J, Gross WL, et al. Nomenclature of systemic vasculitides: proposal of an international consensus conference. Arthritis Rheum 1994;37:187-92.
3. Nielsen HE. Epidemiology of Schönlein-Henoch purpura. Acta Paediatr Scand 1988;77:125-31.
4. Tancrede-Bohin E, Ochonisky S, Vignon-Pennamen MD, Flageul B, Morel P, Rybojad M. Schönlein-Henoch purpura in adult patients: predictive factors for IgA glomerulonephritis in a retrospective study of 57 cases. Arch Dermatol 1997;133:438-42.
5. Lie JT. Nomenclature and classification of vasculitis: plus ça change, plus c'est la même chose [editorial]. Arthritis Rheum 1994;37:181-6.
6. Kawakami T, Watabe H, Mizoguchi M, Soma Y. Elevated serum IgA anticardiolipin antibody levels in adult Henoch-Schönlein purpura. Br J Dermatol 2006;155:983-7.
7. McNeil HP, Chesterman CN, Krilis SA. Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 1991;49:193-280.
8. Harris EN. Antiphospholipid antibodies. Br J Haematol 1990;74:1-9.
9. McNeil HP, Simpson RJ, Chesterman CN, Krilis SA. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci U S A 1990;87:4120-4.
10. Galli M, Comfurius P, Maassen C, Hemker HC, de Baets MH, van Breda-Vriesman PJ, et al. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990;335:1544-7.
11. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease [letter]. Lancet 1990;336:177-8.
12. Roubey RA. Immunology of the antiphospholipid antibody syndrome [review]. Arthritis Rheum 1996;39:1444-54.
13. Wagenknecht DR, McIntyre JA. Changes in beta 2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 1993;69:361-5.
14. Pengo V, Biasiolo A, Fior MG. Autoimmune antiphospholipid antibodies are directed against a cryptic epitope expressed when beta 2-glycoprotein I is bound to a suitable surface. Thromb Haemost 1995;73:29-34.
15. Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood 2003;102:2717-23.
16. Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 2000;43:1982-93.
17. Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies [review]. Arthritis Rheum 2003;48:886-95.
18. Stone JH, Nousari HC. "Essential" cutaneous vasculitis: what every rheumatologist should know about vasculitis of the skin. Curr Opin Rheumatol 2001;13:23-34.
19. Carlson JA, Chen KR. Cutaneous vasculitis update: small vessel neutrophilic vasculitis syndromes. Am J Dermatopathol 2006;28:486-506.
20. Sorensen SF, Slot O, Tvede N, Petersen J. A prospective study of vasculitis patients collected in a five-year period: evaluation of the Chapel Hill nomenclature. Ann Rheum Dis 2000;59:478-82.
21. Tsuchiya N, Kobayashi S, Kawasaki A, Kyogoku C, Arimura Y, Yoshida M, et al. Genetic background of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis: association of HLA-DRB1*0901 with microscopic polyangiitis. J Rheumatol 2003;30:1534-40.
22. Hagen EC, Daha MR, Hermans J, Andrassy K, Csernok E, Gaskin G, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis: EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998;53:743-53.
23. Yang YH, Huang MT, Lin SC, Lin YT, Tsai MJ, Chiang BL. Increased transforming growth factor-β (TGF-β)-secreting T cells and IgA anti-cardiolipin antibody levels during acute stage of childhood Henoch-Schönlein purpura. Clin Exp Immunol 2000;122:285-90.
24. Tizard EJ. Henoch-Schönlein purpura. Arch Dis Child 1999;80:380-3.
25. Austin A, Campbell E, Lane P, Elias E. Nodular regenerative hyperplasia of the liver and coeliac disease: potential role of IgA anticardiolipin antibody. Gut 2004;53:1032-4.
26. D'Agnillo P, Levine JS, Subang R, Rauch J. Prothrombin binds to the surface of apoptotic, but not viable, cells and serves as a target of lupus anticoagulant autoantibodies. J Immunol 2003;170:3408-22.
27. Price BE, Rauch J, Shia MA, Walsh MT, Lieberthal W, Gilligan HM, et al. Anti-phospholipid autoantibodies bind to apoptotic, but not viable, thymocytes in a β 2-glycoprotein I-dependent manner. J Immunol 1996;157:2201-8.